GEVA up +3.62% percent Today $GEVA High is at 76.20 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 12:33 PM

GEVA up +3.62% percent Today $GEVA High is at 76.20 and the Low 71.94 with current volume of 71,499.

Recent News posted below.

Synageva Biopharma Corp GEVA other info.
http://investorshangout.com/Synageva-Biopharm...EVA-54221/

GEVA Synageva Biopharma Corp Recent Headline News

Synageva BioPharma Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 3:05PM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today third quarter 2014 financial results, and provided other business updates.
GEVA: 75.35 (+2.48)

Synageva BioPharma to Present at the Nomura Biotechnology Conference
PR Newswire - Wed Oct 29, 6:05AM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that Sanj K. Patel, President and Chief Executive Officer of Synageva, will present at the Nomura Biotechnology Conference in Boston, MA on Thursday, November 6, 2014, at 8:00 a.m. EST. The presentation will be webcast live and may be accessed from the "Webcasts & Presentations" section of the Investor Relations tab on the home page of Synageva's website at www.synageva.com.
GEVA: 75.35 (+2.48)

Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting
PR Newswire - Thu Oct 23, 3:05PM CDT
Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today two poster presentations of sebelipase alfa data for LAL Deficiency and a satellite symposium at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) annual meeting being held October 23-26, 2014 in Atlanta, GA.
GEVA: 75.35 (+2.48)

Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For Sebelipase Alfa
CNW Group - Tue Oct 21, 3:05PM CDT
Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today the start of a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for sebelipase alfa as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency), a rare genetic disease with significant morbidity and early mortality. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The company anticipates completing the rolling submission of the BLA to the FDA and submitting the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) by the end of January 2015. The BLA and MAA will include data from the global, randomized, double-blind, placebo controlled Phase 3 trial of sebelipase alfa in children and adults with LAL Deficiency, and the Phase 2/3 trial of sebelipase alfa in infants with LAL Deficiency.
GEVA: 75.35 (+2.48)

3 Big-Volume Stocks to Trade for Breakouts
at The Street - Thu Oct 16, 8:26AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
COUP: 15.84 (+0.33), NTES: 92.70 (+0.90), GEVA: 75.35 (+2.48)

Synageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 7:51AM CDT
Synageva BioPharma Corp. (GEVA) was a big mover last session, as its shares rose over 7% on the day.
MACK: 8.58 (-0.12), MYGN: 33.55 (-1.34), HALO: 9.05 (-0.07), GEVA: 75.35 (+2.48)

Sebelipase Alfa Phase 3 Data In Children And Adults With LAL Deficiency Selected For Oral Presentation During The Late-Breaking Session At The Liver Meeting®
PR Newswire - Wed Oct 08, 9:04AM CDT
Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that data from its Phase 3, global clinical study evaluating sebelipase alfa in children and adults with LAL Deficiency has been selected for oral presentation during the late-breaking session at The Liver Meeting®, the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 7-11 in Boston, MA.
GEVA: 75.35 (+2.48)

Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer
PR Newswire - Mon Sep 22, 6:05AM CDT
Synageva BioPharma Corp. ("Synageva"

(NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders announced today the appointment of Robert Bazemore as Chief Operating Officer. Reporting directly to Sanj K. Patel, President and Chief Executive Officer, Robert will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations.
GEVA: 75.35 (+2.48)

Synageva BioPharma To Present At The Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Sep 02, 9:30AM CDT
Synageva BioPharma Corp. ("Synageva"

(NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that Sanj K. Patel, President and Chief Executive Officer of Synageva, will present at the Morgan Stanley Global Healthcare Conference in New York City on Tuesday, September 9, 2014, at 8:00 a.m. EDT. The presentation will be webcast live and may be accessed from the "Webcasts & Presentations" section of the Investor Relations tab on the home page of Synageva's website at www.synageva.com.
GEVA: 75.35 (+2.48)

Aldeyra Therapeutics Expands Drug Development Team in Advance of NS2 Clinical Trials
GlobeNewswire - Tue Sep 02, 7:30AM CDT
Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the expansion of its drug development team with three strategic hires to support upcoming studies for its lead product candidate, NS2.
VRTX: 116.38 (+0.45), GEVA: 75.35 (+2.48), ALDX: 7.53 (+0.41), BAX: 70.57 (-0.04)

Synageva BioPharma(TM) To Present At The Baird 2014 Healthcare Conference
PR Newswire - Tue Aug 26, 9:00AM CDT
Synageva BioPharma Corp. ("Synageva"

(NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that Sanj K. Patel, President and Chief Executive Officer of Synageva will present at the Wedbush Life Sciences Conference in New York City on Tuesday, August 12, 2014, at 8:00 a.m. EDT, and at the Canaccord Genuity Annual Growth Conference in Boston, MA on Wednesday, August 13, 2014, at 8:00 a.m. EDT. The presentations will be webcast live and may be accessed from the "Webcasts & Presentations" section of the Investor Relations tab on the home page of Synageva's website at www.synageva.com.
GEVA: 75.35 (+2.48)

Synageva Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 3:30PM CDT
Synageva BioPharma Corp's second quarter 2014 loss came in at $1.52 per share, much wider than the year-ago loss of 81 cents per share and the Zacks Consensus Estimate of a loss of $1.37.
CRIS: 1.34 (+0.04), GEVA: 75.35 (+2.48), ENZ: 4.95 (+0.01)

Synageva BioPharma(TM) Reports Second Quarter 2014 Financial Results
PR Newswire - Wed Jul 30, 3:05PM CDT
Synageva BioPharma Corp. ("Synageva"

(NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported second quarter 2014 financial results, and provided other business updates.
GEVA: 75.35 (+2.48)

GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors
Business Wire - Thu Jul 10, 8:01AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today the addition of Mark A. Goldberg, M.D. to its Board of Directors. Dr. Goldberg is Executive Vice President, Medical and Regulatory Strategy at Synageva BioPharma Corporation and holds appointments at Brigham and Women's Hospital and Dana Farber Cancer Institute. He is also an Associate Clinical Professor of Medicine at Harvard Medical School.
GEVA: 75.35 (+2.48), GLYC: 7.76 (-0.15)

5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun Jul 06, 6:00AM CDT
There's never a shortage of stocks going the wrong way in any given chunk of time. No stock goes straight up, and sometimes fundamentals can get a bit wobbly. Let's take a closer look at five of this past week's biggest sinkers. Company ...
AYI: 140.32 (-0.07), GEVA: 75.35 (+2.48), STAA: 8.82 (-0.13), NQ: 7.49 (+0.31), ERII: 4.81 (+0.02)

3 Stocks Crushed by the Market This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jul 05, 2:00PM CDT
Shareholders of these three health-care stocks could be wishing for a do-over for the start of July. One of the week's big losers appears to have been hurt by being dropped from a well-known index. Another reported late-stage clinical study results...
GEVA: 75.35 (+2.48), AXDX: 20.44 (+0.09), STAA: 8.82 (-0.13)

Positive Study Results, Patent Grants, Acquisitions, Patient Enrollment, and Earnings Schedule - Analyst Notes on Synageva, OPKO, bluebird bio, BioDelivery Sciences and Haemonetics
PR Newswire - Thu Jul 03, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Synageva BioPharma Corp. (NASDAQ: GEVA), Opko Health Inc. (NYSE: OPK), bluebird bio Inc. (NASDAQ: BLUE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4405-100free.
BDSI: 16.07 (+0.57), BLUE: 41.89 (+0.86), GEVA: 75.35 (+2.48), OPK: 8.58 (+0.26), HAE: 36.60 (-0.22)

Nasdaq stocks posting largest percentage decreases
AP - Tue Jul 01, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
GEVA: 75.35 (+2.48), AXDX: 20.44 (+0.09), STAA: 8.82 (-0.13), IPWR: 7.48 (-0.26), USMD: 7.08 (+0.13), GTWN: 16.75 (+0.27), OBAS: 7.12 (+0.02)

Synageva BioPharma Corp. (GEVA) Stock Research Links

GEVA Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aramco Digital and Avathon Drive Industrial AI Changes

Industrial AI is getting a significant booster shot, thanks to a heavy-hitting alliance between Aramco Digital and Avathon. If you’re scratching your head and thinking, 'Another tech partnership? Who cares?'—well, in this case, you’d be wise to pay attention. How Two Giants Are Teaming Up Imagine Aramco Digital and Avathon as two juggernauts entering the ring—not...

ONTO Faces Fiduciary Duty Investigation Alert

Possible Fiduciary Abuses at Onto Innovation Imagine you’re cruising down the investment highway when, bam, an alert like this pops up in your rearview mirror. It’s time to hit the brakes and figure out what Levi & Korsinsky is up to with this investigation into Onto Innovation Inc. (NYSE: ONTO). They're sniffing around possible breaches of fiduciary duties by some of...

York Urged to Retire Research Macaques After Probe

Undercover Investigation Shakes Up York University If you thought the world of research was all about sterile labs and the pursuit of knowledge, think again. The Jane Goodall Institute (JGI), famed for championing animal welfare, has urged York University to let go of nine long-suffering rhesus macaques. Turns out, these macaques weren't exactly living their best lives....

West Physics Expands Reach with Radiographic Testing Buy

A Strategic Move in Medical Physics When you're at the helm of a ship like West Physics, every strategic move you make sends ripples through the industry. Their recent acquisition of Radiographic Testing Services, Inc. (RTS) is exactly that—one colossal wave. No one who knows the ins and outs of imaging services can scoff at this maneuver. It's a well-calculated step...

ASUS Harnesses AI Power with ProArt RTX Spark PCs

When ASUS throws its hat in the ring, you know it's going for the knockout. At IFA 2026, they're swinging for the fences with their new ProArt lineup—powered by NVIDIA RTX Spark. We're talking serious AI muscle here, up to 1 petaflop worth! What Makes This Lineup a Game Changer? The ProArt series, comprising of the P16 and P14 laptops, alongside the GR1X mini PC, is a...

Kevin Hart & Pragmatic Play Revamp Live Casino Scene

Where Comedy Meets Chances You've got Kevin Hart, larger than life, and then you've got Pragmatic Play—a key player in iGaming. Put them together and you've got an event that might turn the usual casino lights into a full-blown spotlight. They're not just throwing dice, they're shaking up the market with potential way beyond what meets the eye. Okay, so here's the...

AB 2529: New Bill Awaits Governor's Decision

Legislative Milestone or Just Another Step? Hidden Hills, California is causing a bit of a ripple in the state's legislative waters with Assembly Bill 2529. Now that the bill has sailed through the California Legislature with impressive bipartisan support—it passed the State Senate 39-0 and the Assembly 62-4—it's sitting pretty on the Governor's desk. The question...

Robo.ai Surpasses $180 Million in Q2 Revenue Surge

Robo.ai's Financial Rocket Lift-off: Q2 Highlights Who would've thought a single acquisition could propel a company's revenue north of $180 million in just three months? Well, Robo.ai, with its recent grab of Quantum Core Capital (QC Capital), shattered that ceiling, showcasing what a savvy acquisition and a dash of tech wizardry can achieve. Strong Quarter, Stronger...

Nutex Health Breach: Legal Scrutiny and Risks Rise

Cyberattack Unravels at Nutex Health Not just another day in the office for Nutex Health. The Houston-based micro-hospital operator, envisioned as a go-to for healthcare with its 28 facilities across 12 states, now finds itself plunged into a data nightmare. On August 24, 2026, they blew the whistle on unauthorized network activity. By August 31, it wasn’t just a minor...

Geek+ Spurs Growth with 35.5% Order Surge and New Model

Unexpected Surge in Orders Drives Geek+ It looks like Geek+ isn't just playing around in the robotics sandbox anymore. They're delivering some serious results, reporting a 35.5% increase in new signed orders reaching a whopping RMB2.385 billion for the first half of 2026. That's not chump change, and it injects a healthy dose of optimism into their future performance...